General Review of Circulating Tumor DNA/RNA

  • Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility?: a report of the Association for Molecular Pathology.
    Gold B, Cankovic M, Furtado LV, Meier F, Gocke CD. J Mol Diagn. 2015;17(3):209-24.
  • The translational potential of circulating tumour DNA in oncology.
    Patel KM, Tsui DW. Clin Biochem. 2015 Apr 15. doi: 10.1016/j.clinbiochem.2015.04.005.
  • Liquid biopsies: genotyping circulating tumor DNA.
    Diaz LA Jr, Bardelli A. J Clin Oncol. 2014;32(6):579-86.

Circulating Tumor DNA/RNA Analysis in Hematologic Disease

Note especially papers by NeoGenomics scientists Dr. Maher Albitar, Chief Scientific Officer/Director of R&D, and Wanlong Ma, R&D Supervisor.

  • Determining tumor load and biallelic mutation in patients with CALR mutation using peripheral blood plasma [abstract].
    Diep K, Ma W, Albitar F, De Dios I, Agersborg S, Thangavelu M, Brodie S, Albitar M. Blood. 2014;124(21):abstract 1818.
  • Deep sequencing of peripheral blood plasma DNA as a reliable test for confirming the diagnosis of myelodysplastic syndrome [abstract].
    Albitar F, Ma W, Diep K, De Dios I, Agersborg S, Thangavelu M, Brodie S, Albitar M. Blood. 2014;124(21):abstract 1909.
  • Minimal residual disease-based risk stratification in Chinese childhood acute lymphoblastic leukemia by flow cytometry and plasma DNA quantitative polymerase chain reaction.
    Cheng SH, Lau KM, Li CK, et al. PLoS One. 2013;8(7):e69467.
  • MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.
    Ma W, Zhang X, Wang X, Zhang Z, Yeh CH, Uyeji J, Albitar M. Diagn Mol Pathol. 2011;20(1):34-9.
  • Increased integrity of circulating cell-free DNA in plasma of patients with acute leukemia.
    Gao YJ, He YJ, Yang ZL, et al. Clin Chem Lab Med. 2010;48(11):1651-6.
  • JAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasms.
    Ma W, Kantarjian H, Zhang X, Wang X, Zhang Z, Yeh CH, O’Brien S, Giles F, Bruey JM, Albitar M. PLoS One. 2010;5(8):e12165.
  • Plasma levels of JAK2 mRNA in patients with chronic myeloproliferative diseases with and without V617F mutation: implications for prognosis and disease biology. Ma W, Kantarjian H, Zhang X, Yeh CH, Zhang ZJ, Verstovsek S, O’Brien S, Giles F, Albitar M. Int J Lab Hematol. 2010;32(1 Pt 2):95-102.
  • Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications.
    Ma W, Kantarjian H, Zhang X, Jilani I, Sheikholeslami MR, Donahue AC, Ravandi F, Estey E, O’Brien S, Keating M, Giles FJ, Albitar M. Cancer Biomark. 2009;5(1):51-8.
  • Plasma-based detection of clonality in lymphoid malignancies.
    Yeh CH, Tseng R, Albitar M. Eur J Haematol. 2009;82(6):450-3.
  • Quantification of free total plasma DNA and minimal residual disease detection in the plasma of children with acute lymphoblastic leukemia.
    Schwarz AK, Stanulla M, Cario G, et al. Ann Hematol. 2009;88(9):897-905.
  • Higher detection rate of JAK2 mutation using plasma.
    Ma W, Kantarjian H, Zhang X, Sun W, Buller AM, Jilani I, Schwartz JG, Giles F, Albitar M. Blood. 2008;111(7):3906-7.
  • Plasma-based testing as a new paradigm for clinical testing in hematologic diseases.
    Giles FJ, Albitar M. Expert Rev Mol Diagn. 2007;7(5):615-23.
  • Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia.
    Ma W, Tseng R, Gorre M, Jilani I, Keating M, Kantarjian H, Cortes J, O’Brien S, Giles F, Albitar M. Haematologica. 2007;92(2):170-5.
  • Heterogeneity in detecting Abl kinase mutations and better sensitivity using circulating plasma RNA.
    Ma W, Kantarjian H, Jilani I, Gorre M, Bhalla K, Ottmann O, Giles F, Albitar M.
    Leukemia. 2006;20(11):1989-91.
  • Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behaviour.
    Ma W, Kantarjian H, Verstovsek S, Jilani I, Gorre M, Giles F, Cortes J, O’Brien S, Keating M, Albitar M. Br J Haematol. 2006;134(3):341-3.
  • Plasma as a source of mRNA for determining IgV(H) mutation status in patients with chronic lymphocytic leukaemia.
    Ma W, Jilani I, Gorre M, Keating M, Chan H, Tseng R, Kantarjian H, O’Brien S, Giles FJ, Albitar M. Br J Haematol. 2006;133(6):690-2.
  • Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia.
    Rogers A, Joe Y, Manshouri T, Dey A, Jilani I, Giles F, Estey E, Freireich E, Keating M, Kantarjian H, Albitar M.
    Blood. 2004;103(7):2799-801.
  • Use of plasma DNA in detection of loss of heterozygosity in patients with multiple myeloma.
    Ahmed M, Giles F, Joe Y, Weber DM, Jilani I, Manshouri T, Giralt S, De Lima M, Keating M, Albitar M.
    Eur J Haematol. 2003;71(3):174-8.
  • Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA.
    Jilani I, Estey E, Manshuri T, Caligiuri M, Keating M, Giles F, Thomas D, Kantarjian H, Albitar M. Leukemia. 2003;17(1):114-9.